Global Cancer Vaccines Market: Industry Outlook
The global cancer vaccines market reached US$ 8.82 Billion in 2023, with a rise of US$ 9.27 Billion in 2024 and is expected to reach US$ 14.96 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.
The global cancer vaccines market is experiencing significant growth due to rising cancer prevalence, immunotherapy advancements, and personalized medicine adoption. Cancer vaccines, both preventive and therapeutic, are gaining traction as innovative tools in oncology. The COVID-19 pandemic has accelerated research and investment in cancer vaccine technologies. Government initiatives, R&D pipelines, and strategic collaborations between biotech firms and pharmaceutical giants are contributing to market expansion.
However, challenges such as high development costs, regulatory frameworks, and complex cancer biology limit vaccine efficacy. Emerging opportunities like AI-driven vaccine design, neoantigen-based personalized vaccines, and growing demand in emerging economies present promising avenues for future growth. The cancer vaccines market is poised for significant evolution in cancer prevention and treatment.
Global Cancer Vaccines Market: Executive Summary
Global Cancer Vaccines Market Dynamics: Drivers & Restraints
Driver: Rising prevalence of cancer worldwide
The global cancer prevalence is driving the growth of the cancer vaccines market. As a leading cause of mortality, there is a need for more effective, targeted, and less invasive treatment options. Research and development efforts are intensifying towards preventive and therapeutic vaccines that can either stop cancer before it starts or support the immune system in fighting existing tumors.
Healthcare systems and pharmaceutical companies prioritize vaccine-based solutions for long-term immunity and fewer side effects compared to conventional therapies. As awareness among patients and healthcare professionals increases, the demand for innovative cancer vaccines is increasing, making the escalating cancer prevalence a key catalyst for market expansion.
For instance, in 2050, the global cancer burden is expected to rise by 77%, reaching 35 million new cases, largely due to population ageing, population growth, and changes in exposure to risk factors. Key factors include tobacco, alcohol, obesity, and air pollution. High-Income Countries (HICD) are expected to experience the greatest increase in cancer cases, with an additional 4.8 million predicted. However, the proportional increase is most significant in low and medium-HDI countries, with cancer mortality projected to almost double in these regions.
Driver: Advancements in immunotherapy and mRNA vaccine technology
Advancements in immunotherapy and mRNA vaccine technology have significantly shaped the global cancer vaccines market, transforming its trajectory and future potential. Immunotherapy enhances the body's immune response to detect and destroy cancer cells, leading to successful treatments like immune checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies.
Cancer vaccines, particularly therapeutic ones, use tumor-associated or neoantigens to prime the immune system to recognize and attack cancer cells with precision. mRNA vaccine platforms, demonstrated during the COVID-19 pandemic, offer unprecedented speed in development, scalability in manufacturing, and flexibility in design. These advantages have catalyzed the exploration of mRNA technology for cancer vaccines, particularly in creating personalized or tumor-specific vaccines tailored to individual patient profiles.
Companies like Moderna, BioNTech, and CureVac are heavily investing in cancer vaccine pipelines using mRNA platforms that encode tumor antigens and stimulate targeted immune responses. These advancements are enhancing the efficacy and safety of cancer vaccines, reducing barriers to innovation, and establishing cancer vaccines as a vital component of next-generation oncology care.
Restraint: Stringent regulatory approval processes
The global cancer vaccine market faces significant challenges due to stringent regulatory approval processes. These processes require extensive preclinical data and multi-phase clinical trials, which can take years and require substantial financial investment. Cancer is a complex and heterogeneous disease, making it difficult to establish standardized endpoints and biomarkers across patient populations. The lack of historical precedent for personalized or novel vaccine platforms like mRNA or viral vectors can increase scrutiny and uncertainty in approval timelines. These regulatory hurdles not only increase development costs but also pose barriers for smaller biotech companies with limited resources, affecting the pace of innovative cancer vaccines reaching patients in need.
Opportunity: Growth in point-of-care and portable testing solutions
Personalized cancer vaccines, designed using neoantigens, are a promising shift towards precision medicine in the global market. These vaccines target cancer cells with high specificity, sparing healthy tissue, enhancing the potential for robust immune responses, especially in resistant cancers. Tailoring vaccines to each patient's tumor profile improves treatment outcomes and minimizes adverse effects, making them ideal candidates for combination therapies with checkpoint inhibitors or chemotherapy. Advancements in technologies like mRNA and AI-driven antigen discovery are moving closer to commercial viability, with several candidates in clinical trials for melanoma, lung, and gastrointestinal cancers. This growing field presents opportunities for biotech innovation, strategic partnerships, and long-term market growth.
For more details on this report, Request for Sample
Global Cancer Vaccines Market Segment Analysis
The global cancer vaccines market is segmented based on type, cancer type, technology, route of administration, end user, and region.
Type:
The preventive cancer vaccines of this type are expected to have 51.33% of the cancer vaccines market share.
The preventive cancer vaccines segment is a significant driver in the global cancer vaccines market due to the growing focus on early disease prevention, vaccine efficacy awareness, and government initiatives. HPV and Hepatitis B vaccines have proven effective in preventing cancers caused by viral infections, encouraging mass immunization programs worldwide.
For instance, in January 2025, GSK invested £50 million in a collaboration with Oxford to advance cancer research, potentially influencing future vaccine development. The GSK-Oxford Cancer Immuno-Prevention Programme aims to explore the potential of cancer prevention through vaccination.
The widespread adoption of HPV vaccines, particularly among adolescent populations, has contributed to the market's growth. Government policies, improved cold chain logistics, and healthcare infrastructure, particularly in emerging economies, have bolstered vaccine uptake. Technological innovations, increased R&D funding, and global collaborations between public and private entities are streamlining the development and regulatory approval of newer preventive vaccines targeting different virus-related cancers.
As the burden of preventable cancers continues to rise, the demand for cost-effective and scalable preventive solutions is expected to accelerate, cementing the pivotal role of this segment in driving the global cancer vaccines market's growth.
Global Cancer Vaccines Market - Geographical Analysis
The North America global cancer vaccines market was valued at 3.90 Bllion in 2024
North America dominates the global cancer vaccines market due to advanced healthcare infrastructure, high public and private investment in oncology research, and early adoption of immunization technologies. Major pharmaceutical and biotechnology companies are actively involved in vaccine development, clinical trials, and regulatory submissions.
Government support, fast-track FDA approvals, and funding for cancer prevention initiatives accelerate market growth. High awareness about cancer prevention, routine screening programs, and access to preventive healthcare led to strong uptake of HPV and Hepatitis B vaccines. The rising prevalence of lifestyle-related cancers and a well-established reimbursement framework enhance market penetration and patient compliance. For instance, in August 2024, UCLA Health launched a clinical trial using a personalized cancer vaccine to combat aggressive brain tumors in adolescents and young adults.
The Asia-Pacific global cancer vaccines market was valued at 2.17 Billion in 2024
The Asia-Pacific region is experiencing a significant growth in the market for cancer vaccines due to factors such as an aging population, rising cancer incidence, and increased public awareness. Countries like China, India, Japan, and South Korea are investing in national immunization programs and healthcare reforms to improve access to preventive healthcare solutions, including cancer vaccines.
Moreover, economic growth and expanding healthcare infrastructure are making advanced cancer care more accessible. The region's surge in local vaccine manufacturing capabilities and collaborations between domestic and global pharmaceutical players are also contributing to cost reduction and improved vaccine availability.
For instance, in July 2024, Anixa Biosciences received a "Decision to Grant" notice from the Japan Patent Office for its "Vaccine Adjuvants and Formulations" patent application, extending claims for a novel breast cancer vaccine technology beyond the U.S. and European patents previously awarded, according to Anixa Chairman and CEO Dr. Amit Kumar.
Global Cancer Vaccines Market – Major Players
The major players in the cancer vaccines market include Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Dendreon Pharmaceuticals LLC, among others.
Global Cancer Vaccines Market – Emerging Players
The emerging players in the cancer vaccines market include Candel Therapeutics, Elicio Therapeutics, Evaxion, Imugene, Nouscom, OSE Immunotherapeutics, Scancell, and Takis, among others.
Global Cancer Vaccines Market – Key Developments
In March 2025, Everest Medicines administered its personalised mRNA cancer vaccine, EVM16, to the first subject in a first-in-human trial, EVM16CX01. The trial, conducted at Peking University Cancer Hospital in China, aims to assess the vaccine's immunogenicity, safety, preliminary efficacy, and tolerability in individuals with advanced or recurrent solid tumors.
Global Cancer Vaccines Market: Scope
Metrics | Details | |
CAGR | 5.5% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Type | Preventive Cancer Vaccines, Therapeutic Cancer Vaccines |
Cancer Type | Prostate Cancer, Cervical Cancer, Lung Cancer, Bladder Cancer, Others | |
Technology | Protein-based, Nucleic acid-based (DNA, RNA/mRNA), Whole-cell, Viral vector, Dendritic cell, Recombinant/adjuvant. | |
| Route of Administration | Intramuscular, Intravenous, Others |
| End User | Hospitals, Clinics, Cancer Treatment Centers, Government Entities, Others |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
DMI Insights:
The global cancer vaccines market is experiencing significant growth, reaching US$ 9.27 Billion in 2024 and projected to reach US$ 14.96 Billion by 2033 at a CAGR of 5.5%.
This growth is driven by the increasing global cancer burden, immunotherapy preference, and advancements in mRNA technologies and personalized vaccines. Preventive vaccines, particularly for HPV and Hepatitis B, remain dominant with a 61.6% market share.
North America leads the market due to its mature healthcare infrastructure and FDA support, while Asia-Pacific is emerging due to rising incidence rates and healthcare investments. Opportunities in AI-driven neoantigen discovery, point-of-care innovation, and biotech collaborations signal a transformative phase for cancer prevention and treatment. Key players like Merck, GSK, and Dendreon are driving this evolution.
The global cancer vaccines market report delivers a detailed analysis with 57 key tables, more than 71 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more pharmaceutical-related reports, please click here
